Adaptive Biotechnologies Plans to Split Its MRD and Immune Medicine Units
The company expects to decide the best path by year-end 2026.
Already have an account? Sign in.
The company expects to decide the best path by year-end 2026.
Abivax shares fell after Scorpion Capital claimed its ulcerative colitis drug is toxic. The company rejected the report and reaffirmed its Phase 3 data.
CrowdStrike is reportedly in talks to acquire Zscaler in a potential $265 billion cybersecurity deal, one of the largest in the sector.
Canadian Solar shares fell sharply after a report that the solar firm and its Recurrent Energy unit are considering asset sales and a possible Chapter 11 filing.
Be the first to know when deals break, stocks move, or biotech headlines hit.